P115 Clinical Outcome of Crizotinib in Diverse ALK Fusion Partners and Different Detection Methods Treatment Naïve Advanced NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.141
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

P2.01-109 Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-35 Tumor Volume Analysis in ALK-Rearranged NSCLC Treated With Crizotinib: Identifying an Early Marker for Clinical Outcome

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management
2020English

PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Budget Impact of Alectinib in the Treatment of Naïve Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy